Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90

Eur J Med Genet. 2022 Jan;65(1):104403. doi: 10.1016/j.ejmg.2021.104403. Epub 2021 Dec 4.

Abstract

Developmental and epileptic encephalopathies (DEE) are a genetically heterogeneous group of disorders characterised by early onset epilepsy, epileptiform activity on electroencephalogram and associated developmental delay or neuroregression. With the advent of high throughput sequencing, novel gene-disease associations have been described for DEEs. Voltage activated sodium channels (Nav) regulate neuronal excitability. Fibroblast growth factor homologous factors (FHFs) are proteins, which bind to the C terminal cytoplasmic tails of alpha subunits of Nav channels and influence their function and surface expression. Gain of function hemizygous or heterozygous variants in FGF13 (also known as FHF2) were recently identified as the cause for X-linked developmental and epileptic encephalopathy 90 (DEE90; MIM# 301058) in seven individuals from five families, which included one female. We report an additional female, providing further evidence for a novel de novo heterozygous missense variant in FGF13, NM_004114.5: c.14T > G p.(Ile5Ser) causing X-linked DEE90. In addition, we review the genotype and phenotype of affected individuals with DEE90.

Keywords: EEG; FGFs; FHFs; Gain of function; Seizure; Sodium channels.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Epilepsy / genetics*
  • Female
  • Fibroblast Growth Factors / genetics*
  • Genetic Diseases, X-Linked / genetics*
  • Genotype
  • Heterozygote
  • Humans
  • Infant
  • Mutation, Missense
  • Neurodevelopmental Disorders / genetics*
  • Phenotype
  • Seizures / genetics*

Substances

  • fibroblast growth factor 13
  • Fibroblast Growth Factors